WebContact Information Website www.ethris.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office Semmelweisstr. 3 82152 Planegg Germany +49 089 00000000 ETHRIS Timeline 2024 2024 2024 2024 WebDec 21, 2024 · Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms.
Group Leader PhD ethris GmbH, Planegg - ResearchGate
WebAug 21, 2024 · MUNICH & GAITHERSBURG, Md.-- ( BUSINESS WIRE )--Ethris GmbH, a leader in mRNA-based therapeutics with specific expertise in pulmonary disease, today announced a five-year strategic research... WebDec 21, 2024 · Ethris GmbH, a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA … ftp transfer security
Carsten RUDOLPH ethris GmbH, Planegg Research profile
WebDec 21, 2024 · Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The … WebEthris’ proprietary mRNA technology can be targeted to the lungs where it helps to replace, inhibit or augment proteins that are involved in causing or exacerbating respiratory disease. mRNA-based therapeutics may also … WebJul 2016. Steffen Meyer. Martin Woodward. Christina Hertel. [...] Adrian Hayday. APS1/APECED patients are defined by defects in the autoimmune regulator (AIRE) that mediates central T cell ... ftp triatlo